by Stefan Ravello | Jul 20, 2026 | Uncategorized
Advances in biomarker and genetic testing have transformed cancer care, creating new opportunities to personalize treatment and improve outcomes for patients with lung, colorectal, and prostate cancers. As testing recommendations, molecular targets, and treatment...
by Stefan Ravello | Jun 11, 2026 | Hematology-Oncology, Multiple Myeloma
As the treatment landscape for multiple myeloma evolves, emerging Cereblon E3 ligase modulators (CELMoDs) are poised to redefine how clinicians approach relapsed/refractory disease. This course examines how iberdomide and mezigdomide differ from traditional IMiDs...
by Stefan Ravello | May 11, 2026 | Oncology, PARP-Combination Therapy, Prostate Cancer
Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple...
by Stefan Ravello | May 11, 2026 | Breast Cancer, Oncology
Early-stage hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer is the most common breast cancer subtype, accounting for roughly two-thirds to three-quarters of all new breast cancer cases in the United States (U.S.). Endocrine therapy (ET) has long...
by Stefan Ravello | May 11, 2026 | Hematology-Oncology, Multiple Myeloma
Multiple myeloma (MM) is a malignant plasma cell disorder and the second most common blood cancer in the United States (U.S.) Survival has improved markedly with modern therapies – the 5-year survival rate has more than doubled in recent decades – yet myeloma remains...
